BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amnis Corporation Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System


5/22/2008 10:48:26 AM

SEATTLE, May 22 /PRNewswire/ -- Amnis Corporation announced today the commercial release of its Extended Depth of Field (EDF(TM)) option for the ImageStream system. This technology breaks through classical depth of field limitations of high resolution optical systems, thereby improving the performance of the ImageStream system and enabling new applications including high speed analysis of fluorescence in-situ hybridization (FISH). The EDF option can be installed at time of manufacture or in the field to allow the existing customer base to take advantage of this new capability.

"The EDF option uses a combination of specialized optics and unique image processing algorithms to project all structures within the cell onto one crisp plane of focus," said William Ortyn, Amnis' Chief Operating Officer. "Until now this could only be accomplished via conventional confocal image stacking techniques which are very slow and tend to suffer from photo bleaching. The ImageStream with EDF is unhindered by photo bleaching and operates at rates close to 1000 times faster than confocal microscopy. The resulting imagery and analysis capabilities are unparalleled in the cell analysis space setting the stage for the development of fundamentally new research and clinical applications based on the ImageStream platform."

"To create the EDF upgrade we combined WaveFront Coded(TM) technology from [OmniVision-CDM Optics] with our own optimized image deconvolution algorithms, with striking results," said David Basiji, Ph.D., Amnis' President and CEO. "In addition to the optical benefits, the EDF option triples the data collection rate by allowing the instrument to be operated with a larger core stream diameter. One of the most important applications the ImageStream with EDF can now address is FISH in suspension (FISHIS(R)). Counting FISH spots accurately requires that all spots be in focus, no matter where they are in the nucleus ... EDF technology, combined with the tremendous speed and sensitivity of the ImageStream system, will make high throughput FISHIS a reality. With the recent release of IDEAS 3.0 and the current release of the EDF option, the Company continues to make excellent progress in advancing the technological capabilities of our product line.

Amnis Corporation, headquartered in Seattle, WA, develops, manufactures and markets the ImageStream system for high speed imaging of cells in flow. The system generates over 100,000 high resolution cell images per minute with fluorescence sensitivity better than standard flow cytometry. The ImageStream is supported by the IDEAS(R) image analysis package, a highly sophisticated yet easy to use tool for processing hundreds of thousands of images at a time. The software package enables advanced research applications in hematology, immunology and oncology, and provides a critical foundation for the company's clinical applications development.

CONTACT: Guy Page of Amnis Corporation, +1-206-576-6890

Web site: http://www.amnis.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES